Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS). The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-11-06	€1.020	+38.59%	345,297
26-11-05	€0.7360	-0.54%	8,178
26-11-04	€0.7400	0.00%	7,117
26-11-03	€0.7400	+2.21%	9,204
26-11-02	€0.7240	+0.14%	2,218

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Aelis Farma

Company calendar

Market Closed - Euronext Paris 11:55:00 2026-11-06 EST			5-day change	1st Jan Change
1.020 ^EUR	+38.59%		+41.08%	-9.33%

09-15	Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-16	Aelis continues development of AEF0217 in Down syndrome, shares rise

Market Cap	13.87M 15.46M 12.67M 11.57M 21.8M 1.45B 22.49M 153M 60.92M 776M 58.04M 56.79M 2.45B	P/E 2024	-3.61x	P/E 2025	-2.39x
Enterprise Value	11.77M 13.12M 10.75M 9.82M 18.49M 1.23B 19.08M 130M 51.68M 658M 49.24M 48.18M 2.08B	EV / Sales 2024	3.46x	EV / Sales 2025	6.33x
Free-Float	63.56%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	AELIS	Real-time
Deutsche Boerse AG	69O	Delayed
Boerse Muenchen	69O	Real-time
Börse Stuttgart	69O	Delayed

09-15	Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-16	Aelis continues development of AEF0217 in Down syndrome, shares rise
07-16	Aelis Farma Receives Positive Recommendation from Independent Data Monitoring Committee to Continue Phase 2b Study of AEF0217 in People with Down Syndrome Without Modification	CI
04-23	Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-07	Aelis Farma Receives ?458,000 Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases	CI
03-23	Stocks to watch today
03-23	Aelis Farma begins patient enrollment for clinical trial
03-23	Aelis Farma Launches Phase 2B Trial for Down Syndrome Impairments Treatment	MT
03-21	Aelis Farma Announces Successful Start of Recruitment of Phase 2B Clinical Trial with Aef0217 for Treatment of Behavioral and Cognitive Impairments of People with Down Syndrome	CI
01-12	Aelis Farma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome	CI
12-02	European Green Light for Aelis Farma's Phase 2B Trial in Down Syndrome
12-02	Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial with AEF0217 in People with Down Syndrome	CI
25-09-25	Aelis Farma availability of 2025 half-year financial report	RE

Aelis Farma Stock

Stocks

AELIS

FR0014007ZB4

Pharmaceuticals

Valuation: Aelis Farma

Chart: Aelis Farma

Latest news: Aelis Farma

Analysts' recommendations: Aelis Farma

Press Releases: Aelis Farma

News in other languages: Aelis Farma

Quotes and Performance

Price Extremes

Managers and Directors: Aelis Farma

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

11-06	Aelis Farma Announces Positive Results of a Retrospective Study Suggesting That AEF0217 Effects in People With Down Syndrome Translate Into Perceivable Improvement in Real Life	BU
09-24	Aelis Farma: Availability of the 2026 Half-Year Financial Report	BU
09-15	Aelis Farma Reports 2026 Half-Year Financial Results and Presents Progress and Development Outlook	BU
07-16	Aelis Farma Receives a Positive Recommendation From the Independent Data Monitoring Committee to Continue the Phase 2b Study of AEF0217 in People With Down Syndrome Without Modification	BU
06-22	Aelis Farma: Availability of the Description of the Share Buyback Program	BU

11-06	Bourse : Teleperformance avertit, TripAdvisor perd le nord, Airbnb s'en sort
11-06	Des données encourageantes dans la trisomie 21 pour Aelis Farma
11-06	Very Bad Trip pour le boom de l'IA
11-06	Aelis Farma annonce les résultats positifs d’une étude rétrospective suggérant que les effets d’AEF0217 chez les personnes avec une trisomie 21 se traduisent par des améliorations perceptibles de la vie quotidienne
09-24	Aelis Farma : Mise à disposition du rapport financier semestriel 2026

1 day	+38.59%
1 week	+41.08%
Current month	+41.08%
1 month	+24.39%
3 months	-2.49%
6 months	-18.40%
Current year	-9.33%

1 week	0.72	1.14
1 month	0.61	1.14
Current year	0.61	2.3
1 year	0.61	2.3
3 years	0.61	13.6
5 years	0.61	14.48
10 years	0.61	14.48

Manager	Title	Age	Since
Pier Vincenzo Piazza CEO	Chief Executive Officer	65	2016-12-31
Marie Line Lefevre DFI	Director of Finance/CFO	-	-
Helle Mengel CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Pier Vincenzo Piazza BRD	Director/Board Member	65	2016-12-31
Anders Gersel Pedersen CHM	Chairman	75	2019-12-31
Brahim Guetarni BRD	Director/Board Member	49	2020-12-31

Date	Insider	Type	Quantity	% Market Cap.
9/1/23	Vincenzo Piazza Pier	Buy	200	0.0016%
8/4/23	Vincenzo Piazza Pier	Buy	10	0.0001%
7/12/23	Vincenzo Piazza Pier	Buy	20	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AELIS FARMA	+38.59%	+41.08%	-7.27%	-92.39%	15.46M
ELI LILLY AND COMPANY	-0.79%	-4.48%	+44.44%	+127.49%	1,206B
JOHNSON & JOHNSON	+1.43%	+1.11%	+47.73%	+82.08%	665B
ABBVIE INC.	+1.07%	-1.21%	+32.99%	+106.31%	515B
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	381B
MERCK & CO., INC.	-0.14%	-1.87%	+71.05%	+40.63%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	307B
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	289B
AMGEN INC.	+0.03%	-1.20%	+45.89%	+68.76%	249B
GILEAD SCIENCES, INC.	-0.41%	-2.22%	+35.24%	+105.68%	207B
Average	+3.78%	+2.72%	+35.64%	+59.67%	417.98B
Weighted average by Cap.	-0.04%	-1.96%	+42.24%	+88.38%

	2024	2025
Net sales	5.56M 6.2M 5.08M 4.64M 8.74M 583M 9.02M 61.27M 24.43M 311M 23.28M 22.78M 982M	2.08M 2.32M 1.9M 1.74M 3.28M 218M 3.38M 22.96M 9.15M 117M 8.72M 8.53M 368M
Net income	-7.46M -8.31M -6.81M -6.22M -11.72M -781M -12.09M -82.13M -32.75M -417M -31.2M -30.53M -1.32B	-6.43M -7.17M -5.88M -5.37M -10.11M -674M -10.43M -70.88M -28.26M -360M -26.93M -26.35M -1.14B
Net Debt	-7.97M -8.88M -7.28M -6.65M -12.52M -835M -12.92M -87.76M -35M -446M -33.34M -32.63M -1.41B	-2.1M -2.34M -1.92M -1.75M -3.31M -220M -3.41M -23.17M -9.24M -118M -8.8M -8.61M -371M